Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Commences European trials of the InSynch ICD 34 Joule implantable cardioverter defibrillator for heart failure patients at risk of sudden cardiac death. The device features GEM DR ICD technology, a PR Logic dual chamber detection algorithm and Patient Alert performance monitoring. Both the InSynch ICD and the InSynch system (which provides cardiac resynchronization and was launched abroad in August 1998), are used with Medtronic's Attain model 2187 and 2188 left ventricular leads, which have been released outside the U.S. Both the InSynch and the Attain 2187 and 2188 leads are currently in clinical trials in the U.S. Separately, Medtronic announces the first human implants in Germany of the AT500, a 20 g, 14 cc dual chamber, rate responsive stimulator for bradycardia patients with intermittent atrial tachyarrhythmias and atrial fibrillations
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel